Drugs / Neurexan
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials · 2 missed | ||||||
| Phase 1/2 | NCT01703819 | Oct 2012 → Apr 2013 | acute stress disorder | Biologische Heilmittel Heel GmbH | Completed | Missed primary |
| Phase 1/2 | NCT01703832 | Oct 2012 → Apr 2013 | acute stress disorder | Biologische Heilmittel Heel GmbH | Completed | Missed primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT06278077 | Sep 2023 → Jan 2026 | insomnia | Biologische Heilmittel Heel GmbH | Completed | No outcome recorded |
| Phase 2 | NCT02602275 | Aug → Dec 2015 | acute stress disorder | Biologische Heilmittel Heel GmbH | Completed | Mixed |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neurexan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01703819 ↗ |
| Known as | Nx4 | “The objective of this study was to assess the efficacy profile of Nx4 (Neurexan ®) in an acute experimental stress setting.” PMID 26772822 ↗ Jan 2016 |
| Route | Oral | “Participants receive totally three tablets of either Neurexan® or Placebo per treatment period orally.” NCT02602275 ↗ |